Table 2.

ROC analysis of MRS changes in relation to PFS-6 and relative to 12-mo survival

	Change From Baseline	Wk 2	Wk 8	Wk 16
ROC analysis of MRS changes in relation to PFS-6
Tumor	NAA/Cho	0.50 (0.09, 0.91)	0.85 (0.53, 1)	0.75 (0.21, 1)
	Cho/Cr	0.54 (0.14, 0.95)	0.83 (0.47, 1)	1.00 (1, 1)
	NAA/Cr	0.46 (0, 0.99)	0.60 (0.11, 1)	0.46 (0, 1)
Periphery	NAA/Cho	0.39 (0, 0.88)	0.47 (0.02, 0.92)	1.00 (1, 1)
	Cho/Cr	0.52 (0.13, 0.91)	0.41 (0.01, 0.80)	1.00 (1, 1)
	NAA/Cr	0.54 (0.06, 1)	0.63 (0.22, 1)	0.93 (0.73, 1)
ROC analysis of MRS changes in relation to 12-mo survival
Tumor	NAA/Cho	0.42 (0, 0.92)	0.80 (0.47, 1)	0.80 (0.45, 1)
	Cho/Cr	0.42 (0, 0.88)	0.78 (0.44, 1)	0.73 (0.19, 1)
	NAA/Cr	0.67 (0.25, 1)	0.60 (0.17, 1)	0.57 (0.03, 1)
Periphery	NAA/Cho	0.60 (0.20,1)	0.58 (0.22, 0.95)	1.00 (1, 1)
	Cho/Cr	0.72 (0.36, 1)	0.50 (0.13, 0.87)	0.89 (0.63, 1)
	NAA/Cr	0.50 (0.06, 0.94)	0.78 (0.47, 1)	1.00 (1, 1)

ROC analysis with empirical estimates of AUC (95% CI).

AUC ≥ 0.85 and lower bound of the 95% CI > 0.5 are highlighted in bold non-italics.

AUC > 0.75 and lower bound of the 95% CI > 0.4 are highlighted in bold italics.